Melanotan: A Melanocortin Receptor Agonist Family for Pigmentation and Photoprotection

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to Melanotan-II or any related unregulated melanocortin agonist. Melanotan-II is not FDA-approved for human use. Melanotan-I (afamelanotide, Scenesse) is FDA-approved only for erythropoietic protoporphyria (EPP) and is available solely by prescription through licensed providers for that indication. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

The word "melanotan" circulates in tanning forums, biohacking communities, and dermatology clinics. But it refers to two fundamentally different compounds that share a common origin and almost nothing else in terms of regulatory standing, safety profile, or appropriate use. One has completed Phase 3 clinical trials, received FDA approval for a rare photosensitivity disorder, and has a documented long-term safety record. The other has no approved indication anywhere in the world, is sold in unregulated gray markets as an injectable tanning agent, and has been linked in the peer-reviewed literature to melanoma, severe systemic toxicity, and unprovoked priapism.

This article explains what the melanotan class is, how each compound works through the melanocortin receptor system, what the clinical evidence shows for the approved compound, and what the safety literature documents for the unregulated one.

Key Takeaways

• Regulatory Status (MT1): Melanotan-I (afamelanotide, Scenesse) is FDA-approved and EMA-approved for erythropoietic protoporphyria (EPP) in adults. Available only by prescription for that indication. As of April 2026, no other indication is approved.
• Regulatory Status (MT2): Melanotan-II has no approved indication anywhere in the world. It is not legally marketed for human use. The UK MHRA has issued warnings against its use. Superpower Health does not offer this substance.
• Research Stage: MT1 has Phase 3 RCT data and post-approval safety follow-up. MT2 research includes Phase 1 data and multiple published case reports of serious adverse events.
• Availability: Scenesse (MT1) is available only through specialist prescribers for EPP. MT2 is not legally available for human use; products sold online are unregulated and carry significant contamination and dosing risks.
• Prescribing information (MT1): View afamelanotide compound reference data (PubChem CID 2656580)
• What the melanotan class is: Synthetic analogs of alpha-melanocyte-stimulating hormone (α-MSH) that activate melanocortin receptors, most prominently MC1R in melanocytes, to stimulate eumelanin production.
• What the evidence shows: MT1 demonstrated significant increases in pain-free sun exposure versus placebo in two Phase 3 RCTs in EPP patients. MT2 has no completed efficacy RCTs and is associated in case reports with melanoma, nevi changes, severe toxicity, and vascular events.

Where Melanotan Comes From and How the Class Works

Origin and discovery

The melanotan compounds were developed at the University of Arizona in the 1980s and 1990s by Mac Hadley, Victor Hruby, and colleagues, starting from alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring 13-amino acid peptide produced in the pituitary that regulates skin pigmentation, energy balance, and inflammatory responses. The research goal was to create a synthetic analog stable enough to function as a sunless tanning agent and potentially reduce skin cancer risk from UV exposure. As Hadley and Dorr described in their 2006 review in Peptides, the program first developed NDP-MSH (Nle4, D-Phe7-α-MSH), later designated Melanotan-I or afamelanotide, as a potent, metabolically stable analog. Melanotan-II was subsequently synthesized as a cyclic analog with a shorter structure and broader receptor activity profile. A 1996 pilot Phase 1 study by Dorr and colleagues, published in Life Sciences, administered subcutaneous Melanotan-II (starting at 0.01 mg/kg and escalating to 0.025–0.03 mg/kg) every other weekday for 2 weeks to 3 healthy male volunteers at the University of Arizona; two of the three developed increased facial, upper-body, and buttock pigmentation, and spontaneous penile erections lasting 1–5 hours occurred in tandem with a stretching-and-yawning complex — establishing the pigmentary and off-target effects that would define both branches of the research program. The very small sample size is an important limitation of this foundational dataset.

The melanocortin receptor system

Both MT1 and MT2 act through the melanocortin receptor family, a group of five G-protein-coupled receptors designated MC1R through MC5R. Understanding which receptors each compound activates explains why they have fundamentally different effect profiles. MC1R is expressed primarily on melanocytes and controls pigmentation by stimulating eumelanin synthesis over phaeomelanin: the dark, UV-protective pigment rather than the lighter, reddish pigment. A 2016 review by Wolf Horrell and colleagues in Frontiers in Genetics described MC1R as the principal receptor through which melanocortin signaling drives eumelanin production, UV tolerance in melanocytes, and DNA repair activation. A more recent 2023 review by Mun and colleagues in the International Journal of Molecular Sciences updated the mechanistic picture, documenting how MC1R agonism activates the cAMP-MITF-tyrosinase cascade responsible for melanin synthesis. MC3R and MC4R are expressed in the central nervous system and regulate energy homeostasis, appetite, and sexual function. MC5R is found in exocrine glands and plays a role in secretory function. As reviewed by Novoselova and colleagues in 2018 in Best Practice and Research in Clinical Endocrinology and Metabolism, the full receptor system spans pigmentation, energy balance, the hypothalamic-pituitary-adrenal axis, sexual function, and inflammatory modulation.

Why MT1 and MT2 differ in their effects

The key pharmacological distinction is receptor selectivity. Afamelanotide (MT1) binds preferentially to MC1R. Its effects are substantially localized to melanocyte activation and eumelanin synthesis, which is why the clinical program focused on photoprotection in melanin-deficient or photosensitive patients. Melanotan-II is structurally distinct: it is a cyclic heptapeptide analog with lower receptor selectivity, binding to MC1R, MC3R, MC4R, and MC5R. Laiho and Murray, writing in Endocrinology in 2022, characterized melanocortin receptor pleiotropy in detail, noting that MC4R activation mediates sexual arousal and erectile function while also influencing appetite suppression. As Cai and Hruby reviewed in Current Protein and Peptide Science in 2016, MT2's non-selectivity across MC3R and MC4R is the mechanistic source of the side effects observed in human studies: nausea, facial flushing, spontaneous penile erection, and appetite suppression. This broad receptor engagement is also what drove the development of bremelanotide, a more MC4R-selective analog that eventually received FDA approval for a specific indication, as a successor compound.

Melanotan-I (Afamelanotide) and the Evidence for Erythropoietic Protoporphyria

What erythropoietic protoporphyria is and why MT1 was studied for it

Erythropoietic protoporphyria (EPP) is a rare inherited disorder caused by a deficiency of ferrochelatase, the enzyme that incorporates iron into protoporphyrin IX to form heme. Without normal ferrochelatase activity, protoporphyrin IX accumulates in red blood cells and is released into skin tissue, where it absorbs visible light and generates reactive oxygen species. Patients experience intense, painful phototoxic reactions following even brief sun exposure. Because afamelanotide stimulates MC1R-driven eumelanin production, increasing the skin's natural photoprotective pigment, it was hypothesized that preloading melanin stores would reduce phototoxic activation in EPP skin.

Phase 3 clinical trial evidence

The pivotal evidence is from two multicenter, double-blind, placebo-controlled Phase 3 randomized trials reported by Langendonk, Balwani, Anderson, and colleagues in 2015 in the New England Journal of Medicine. The European Union trial (n = 74 EPP adults) and the United States trial (n = 94 EPP adults) randomized patients 1:1 to subcutaneous 16 mg afamelanotide implants or placebo every 60 days. In the US study, the median duration of pain-free direct sun exposure over 6 months was 69.4 hours in the afamelanotide group versus 40.8 hours in the placebo group (p = 0.04); in the EU study, the median pain-free sun exposure over 9 months was 6.0 hours versus 0.8 hours (p = 0.005), with a lower number of phototoxic reactions in the afamelanotide group (77 vs. 146, p = 0.04). Implant-site reactions, nausea, and fatigue were the most commonly reported adverse events, and the side-effect profile was considered acceptable. The compound received EMA approval in 2014 and FDA approval in 2019 for EPP in adults. Long-term follow-up was provided by Biolcati, Marchesini, Sorge, and colleagues in a 2015 observational study in the British Journal of Dermatology, which followed 115 ambulatory EPP patients treated with a total of 1,023 afamelanotide implants over up to 8 years at two porphyria centers (Rome and Zurich) and documented statistically significant improvements in light tolerance, high compliance, and low discontinuation rates. These data formed the basis for the approved indication and the post-approval safety record.

The mechanism behind the photoprotective effect

Afamelanotide is administered as a subcutaneous biodegradable implant that releases the peptide over approximately 60 days. MC1R agonism drives melanocyte differentiation and eumelanin synthesis in the epidermis. Eumelanin absorbs and scatters UV and visible light, reducing photon penetration to dermal layers and limiting protoporphyrin photoactivation. This is not a tanning intervention in the cosmetic sense: it is a targeted melanocortin pharmacology application for a specific metabolic defect. The approved formulation is designed for precisely this narrow indication.

Melanotan-II: The Unregulated Tanning Compound and Its Safety Record

How MT2 became a gray-market product

Following the University of Arizona research program's publication of early Phase 1 MT2 data, including the erection-inducing effects observed in a 1998 double-blind, placebo-controlled crossover trial in 10 men with psychogenic erectile dysfunction by Wessells and colleagues, published in the Journal of Urology (subcutaneous MT-II at 0.025 mg/kg produced clinically apparent erections in 8 of 10 subjects, with mean duration of tip rigidity >80% of 38.0 minutes versus 3.0 minutes on placebo, p = 0.0045; transient nausea and stretching–yawning were the main adverse events), MT2 attracted significant off-label and gray-market interest. Products described as Melanotan-II began circulating online as injectable tanning agents and, in some markets, as sexual function compounds. As Langan and colleagues noted in a widely cited 2010 editorial in the British Journal of Dermatology, these products were not manufactured under pharmaceutical quality standards, had no regulatory oversight, and entered a market where buyers lacked the clinical context to evaluate their risks. Del Marmol and colleagues, writing in Pigment Cell and Melanoma Research in 2009, characterized this as a public-health problem: the same receptor biology that gives MT2 its tanning effect also makes it a potent stimulant of melanocytes, with unknown implications for pre-existing nevi and melanocyte-derived malignancies.

Nevi darkening and the melanoma signal

Stimulating MC1R drives eumelanin production in all melanocytes, not just those in normal skin. Melanocytic nevi (moles) contain melanocytes, and their activation by exogenous melanocortin agonism has been observed in published case reports. Cousen and colleagues described eruptive melanocytic naevi following melanotan injection in a 2009 case report in the British Journal of Dermatology, one of the earliest published descriptions of this phenomenon. Burian and Jemec reviewed the eruptive melanocytic nevi literature in 2019 in the American Journal of Clinical Dermatology, including melanotan-induced cases, and noted that the nevi darkening and new nevi formation observed in these patients represent a concerning response in a tissue known for malignant transformation potential.

Multiple case reports have documented melanoma in MT2 users. Hjuler and Lorentzen reported a melanoma case associated with melanotan-II use in 2014 in Dermatology, and Paurobally and colleagues published a case report titled "Melanotan-associated melanoma" in the British Journal of Dermatology in 2011. In 2025, Yassin Alsabbagh and colleagues published a case report in the International Journal of Oral and Maxillofacial Surgery raising concern that intranasal Melanotan-II use may be a risk factor for oral mucosal malignant melanoma. This is the most recent published safety signal in this area. As Habbema and colleagues established in their comprehensive 2017 review in the International Journal of Dermatology, the totality of the literature on gray-market α-MSH analogue use identifies dysplastic nevi, melanoma association, and the absence of dermatologic monitoring as the primary risk concerns. Whether MT2 causes melanoma through a direct mutagenic mechanism, or whether it preferentially activates pre-existing dysplastic melanocytes, cannot be established from case reports alone. What the literature establishes clearly is that the signal exists, it has appeared in multiple independent reports across more than a decade, and it has not been resolved by any controlled prospective study.

Systemic toxicity and acute adverse events

Beyond the dermatological signal, published case reports document a range of serious systemic adverse events associated with MT2. Nelson and colleagues reported a case of severe systemic toxicity including rhabdomyolysis following Melanotan-II injection in 2012 in Clinical Toxicology. Devlin and colleagues reported a case of priapism following MT2 overdose in the same journal in 2013, directly illustrating the MC4R-mediated erection effect escalating to a medical emergency. Mallory and colleagues published an additional priapism case associated with melanotan tanning injection in Sexual Medicine in 2021, confirming this is not an isolated event. Peters and colleagues reported a case of renal infarction attributed to MT2 in CEN Case Reports in 2020, documenting a vascular adverse-event signal that extends beyond the skin and reproductive domains. Nausea and facial flushing are among the most commonly reported acute effects, consistent with MT2's broad melanocortin receptor engagement.

The unregulated sourcing problem

Products sold online as Melanotan-II are not subject to pharmaceutical manufacturing standards, purity verification, or dose calibration. Habbema and colleagues' 2017 review specifically identified counterfeiting and sourcing contamination as compounding factors in the adverse-event picture: what is sold as MT2 may contain other peptides, microbial contaminants, impurities from synthesis, or incorrect quantities of the active compound. There is no legal or regulated supply chain for MT2 in the United States, the United Kingdom, or the European Union. The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued regulatory warnings against the use of melanotan products. Any product sold in this market is by definition operating outside the oversight frameworks designed to establish pharmaceutical-grade safety.

MT1 vs. MT2: The Critical Distinction

This comparison is for scientific context only. These compounds have fundamentally different regulatory statuses and evidence bases.

Melanotan-I (afamelanotide/Scenesse) and Melanotan-II are both synthetic α-MSH analogs that activate MC1R, but they diverge substantially in receptor selectivity, evidence base, and regulatory standing. MT1 is a linear analog with preferential MC1R activity, a completed Phase 3 development program, FDA and EMA approval, a defined patient population (EPP adults), a pharmaceutical-grade formulation, and post-approval safety monitoring. MT2 is a cyclic analog with activity across MC1R, MC3R, and MC4R; no completed efficacy RCTs; no regulatory approval anywhere; documented case reports of serious adverse events including melanoma association, priapism, rhabdomyolysis, and renal infarction; and a supply chain consisting entirely of unregulated online vendors. The receptor non-selectivity that makes MT2 more potent as a tanning agent is the same property that generates its off-target systemic effects. The bremelanotide program, which developed a more MC4R-selective agonist from the MT2 research lineage, received FDA approval for hypoactive sexual desire disorder, as reviewed by Dhillon and Keam in 2019 in Drugs. The pivotal evidence came from the two identical RECONNECT Phase 3 trials (Studies 301 and 302) reported by Kingsberg and colleagues in Obstetrics and Gynecology in 2019, which randomized 1,267 premenopausal women with HSDD (mean age 39 years) 1:1 to as-needed subcutaneous bremelanotide 1.75 mg versus placebo over 24 weeks; the co-primary outcomes showed increases of 0.30–0.42 on the Female Sexual Function Index-desire domain (p < 0.001) and decreases of −0.29 to −0.37 on the Female Sexual Distress Scale–Desire/Arousal/Orgasm item 13 (p ≤ 0.005), with nausea, flushing, and headache (each ≥10%) as the most common treatment-emergent adverse events. The 52-week open-label extension reported by Simon and colleagues in Obstetrics and Gynecology in 2019 enrolled 684 of 856 eligible completers (272 finishing the extension) and documented sustained FSFI-desire gains of 1.25–1.30 with nausea (40.4%), flushing (20.6%), and headache (12.0%) as the most frequent drug-related events — a high discontinuation rate that honestly limits how strongly the long-term tolerability signal can be read. Exit-study patient-experience data from Koochaki and colleagues in 2021 in the Journal of Women's Health confirmed meaningful benefit in women who chose to continue therapy. That program represents the regulated, controlled evolution of this receptor biology into an approved clinical product.

Regulatory and Legal Status

Melanotan-I (afamelanotide/Scenesse)

As of April 2026, afamelanotide (Scenesse) is an FDA-approved prescription drug for the prevention of phototoxicity in adults with erythropoietic protoporphyria. It is also EMA-approved. It is available only through specialist prescribers for this indication and is not legally obtainable for cosmetic tanning purposes. Its use outside the approved indication is off-label and carries prescriber responsibility. Scenesse is not available through Superpower Health.

Melanotan-II

As of April 2026, Melanotan-II has no approved indication in the United States, the United Kingdom, the European Union, or any other major regulatory jurisdiction. It is not classified as an FDA 503A Category 2 bulk drug substance in the same formal pathway as small-molecule research compounds; it sits in an unapproved, unclassified status that has attracted regulatory enforcement attention in the UK, where the MHRA has issued direct warnings to consumers and vendors. Products sold online as MT2 are unlicensed medicines in the UK and unapproved new drugs in the United States. There is no legal pathway to obtain pharmaceutical-grade Melanotan-II for human use.

What this means practically

For anyone who has encountered Melanotan-II through online communities or tanning forums, the practical implication is clear: no legitimate pharmaceutical manufacturer produces it under quality-controlled conditions, no physician can prescribe it for a recognized indication, and no regulatory body has evaluated its safety and efficacy through the review process that governs approved medicines. The products available are research chemicals sold through networks that operate outside pharmaceutical oversight. The adverse-event case reports in the peer-reviewed literature represent documented harms in real people who used products from this market.

Safety: What the Literature Documents

MT2-specific safety concerns

The safety concerns documented for Melanotan-II are serious, multi-system, and not theoretical. They include nevi darkening and new melanocytic nevi formation; multiple published case reports linking MT2 use to melanoma diagnosis; acute systemic toxicity including rhabdomyolysis; priapism (a medical emergency requiring urgent intervention); renal vascular events; and gastrointestinal effects including nausea and vomiting. The 2017 comprehensive review by Habbema and colleagues represents the most thorough synthesis of this literature, covering dysplastic nevi, melanoma association, cardiovascular effects, GI effects, and the sourcing problem. The concern is not that every person who has injected gray-market MT2 has developed melanoma. The concern is that the compound drives melanocyte activation through a receptor system known to play a role in melanoma biology, the literature contains multiple independent melanoma case reports across a 15-year period, and no prospective controlled safety study has ever been conducted.

Absence of long-term safety data in unapproved contexts

For MT1 in EPP, long-term observational safety data exist and are reassuring within the approved indication and dosing framework. Outside that framework, there is no data. For MT2, the safety data consists almost entirely of adverse-event case reports and the absence of any controlled trial designed to characterize its risk profile. Anyone using MT2 outside a registered clinical trial is effectively acting without a known safety profile for their specific use case.

Who Should Not Use Melanotan-II

Based on the proposed mechanism and the documented adverse-event literature, the following groups face elevated risk.

• Individuals with a personal or family history of melanoma or atypical nevi: MC1R activation drives melanocyte stimulation in all melanocytic tissue, including dysplastic cells
• Individuals with fair skin and MC1R loss-of-function variants: MC1R polymorphisms are associated with elevated melanoma risk; adding exogenous MC1R stimulation in this genotype is a concern with no controlled safety data
• Anyone with active or suspected hormone-sensitive conditions: MT2's MC3R and MC4R activity affects neuroendocrine signaling in ways that remain incompletely characterized
• Men who have experienced spontaneous erection or priapism: MC4R stimulation can precipitate erection; priapism requires urgent medical intervention and can cause permanent tissue injury
• Individuals with cardiovascular or renal disease: published case reports include renal infarction and cardiovascular effects
• Pregnant or breastfeeding individuals: no safety data exist for these populations
• Anyone not under active medical supervision with access to emergency care: the systemic adverse events documented in the literature require prompt clinical management

Which Biomarkers Are Relevant if You Are Exploring Melanocortin Biology?

Melanotan compounds engage multiple physiological systems beyond pigmentation. Understanding your biological baseline is a reasonable starting point for evaluating any investigational compound, and it is particularly relevant here given MT2's documented effects on melanocyte activity, hormonal signaling, and vascular function.

• Estradiol and testosterone: MC3R and MC4R activation influences hypothalamic-pituitary signaling and can affect sex hormone axis activity. A baseline of total testosterone and estradiol provides context for any downstream hormonal changes.
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH): Melanocortin receptor activity in the hypothalamus can modulate gonadotropin-releasing hormone pulsatility. A baseline of LH and follicle-stimulating hormone establishes the upstream pituitary-gonadal state.
• High-sensitivity CRP (hs-CRP): Melanocortin receptors, including MC3R, are expressed on immune cells and have anti-inflammatory roles. Baseline hs-CRP provides a reference for systemic inflammatory status before introducing any immunomodulatory compound.
• Complete metabolic panel (liver and kidney function): The renal vascular adverse events documented in the MT2 case literature, and the general requirement for baseline organ-function data before any investigational compound, make baseline renal and hepatic markers relevant.
• Complete blood count (CBC): Rhabdomyolysis and systemic toxicity affect multiple blood parameters. A baseline CBC, including red cell indices and hemoglobin, provides reference values for detecting acute changes.
• IGF-1: MC4R signaling intersects with growth hormone axis activity. IGF-1 provides a proxy for the somatotropic background against which any peptide with neuroendocrine effects operates.

When to Take This Seriously

If you are interested in photoprotection, the evidence-based starting point is dermatological assessment, UV-protective behaviors, and for those with EPP, referral to a specialist who can evaluate eligibility for Scenesse under its approved indication. If MT2's sexual function effects are the attraction, bremelanotide (Vyleesi) represents the regulated, FDA-approved development of that same receptor biology, studied in controlled trials and available through licensed providers. The pattern in melanocortin pharmacology is that the research-derived compounds of interest tend to produce regulated successors with narrower receptor selectivity, better-characterized safety profiles, and legitimate prescribing pathways. Those successors are worth understanding before pursuing gray-market compounds that share a mechanism but lack the oversight framework.

That principle, understanding the biology and the evidence before making any clinical decision, is what drives Superpower's approach to preventive health: objective biomarker data first, clinical context second, and decisions grounded in what the evidence actually shows rather than what the forums claim.

IMPORTANT SAFETY INFORMATION

Melanotan-II is NOT FDA-approved for any indication and is not legally marketed for human use in the United States, the United Kingdom, or the European Union. Superpower Health does not prescribe, sell, compound, or facilitate access to Melanotan-II or any unregulated gray-market melanocortin agonist. Products sold online as Melanotan-II are unregulated and may contain contaminants, incorrect dosing, or misidentified compounds.

Melanotan-I (afamelanotide, Scenesse) is an FDA-approved prescription drug indicated only for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It is available solely by prescription through specialist providers for that indication. Its use outside the approved indication is off-label and the responsibility of the prescribing clinician. Scenesse is not available through Superpower Health.

Do not use Melanotan-II if you have: a personal or family history of melanoma or dysplastic nevi; MC1R loss-of-function variants associated with elevated melanoma risk; active or suspected hormone-sensitive conditions; a history of priapism or cardiovascular or renal disease; or if you are pregnant or breastfeeding. This list is not exhaustive.

Warnings associated with Melanotan-II use (documented in peer-reviewed case reports): nevi darkening and new melanocytic nevi formation; melanoma (multiple independent case reports, 2011 to 2025); priapism (a urological emergency requiring immediate medical care); rhabdomyolysis and severe systemic toxicity; renal infarction and vascular events; nausea, facial flushing, and vomiting. These are documented harms in published medical literature, not theoretical concerns.

There is no controlled clinical safety data for Melanotan-II in humans. No Phase 2 or Phase 3 safety or efficacy RCT has ever been completed for MT2. Gray-market MT2 products have not been evaluated for purity, potency, or sterility by any regulatory agency.

This page is not medical advice. Always consult a qualified healthcare provider before making any health decision. Full prescribing information for afamelanotide (Scenesse) is available at dailymed.nlm.nih.gov.

Additional Questions

What are the side effects of melanotan?

For MT1 (Scenesse) in its approved indication, the most commonly reported side effects in Phase 3 trials include implant site reactions, nausea, and fatigue. For MT2, which has no approved indication and no controlled safety profile, documented adverse events in case reports include nausea, facial flushing, spontaneous penile erection, priapism requiring urgent intervention, nevi darkening and new nevi formation, melanoma diagnosis, rhabdomyolysis, and renal infarction. The MT2 adverse-event profile reflects its broad receptor activity and the complete absence of pharmaceutical manufacturing standards in gray-market supply.

Is melanotan the same as bremelanotide (PT-141 or Vyleesi)?

No. Bremelanotide (Vyleesi) is a cyclic peptide that evolved from the MT2 research lineage but was developed specifically as a more MC4R-selective compound, studied in controlled clinical trials, and FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women. As Dhillon and Keam reviewed in 2019 in Drugs, bremelanotide represents a distinct regulatory and pharmacological development from the original melanotan compounds. Comparing bremelanotide's approval to MT2 is not valid: they have fundamentally different receptor profiles, evidence bases, and regulatory statuses.

What does the MHRA say about melanotan?

The UK Medicines and Healthcare products Regulatory Agency has issued direct consumer warnings against melanotan products, specifically addressing the injectable tanning agents sold as Melanotan-II. The MHRA has characterized these products as unlicensed medicines, noted the contamination and dosing risks from unregulated manufacturing, and highlighted the dermatological safety concerns documented in the peer-reviewed literature. As of April 2026, MT2 products remain subject to regulatory action in the UK.